Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 5 May 2026, driven primarily by an improvement in technical indicators despite persistent fundamental challenges. The company’s technical trend has shifted from mildly bearish to sideways, prompting a reassessment of its outlook. However, weak financial performance and long-term profitability concerns continue to weigh on the stock’s prospects.

Solara Active Pharma Sciences Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade to 'Sell' from 'Strong Sell', the stock exhibits a complex interplay of bullish and bearish signals across key technical indicators, reflecting a nuanced market sentiment.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a reassessment of the company’s outlook. However, the analysis and financial metrics discussed here represent the stock’s current position as of 25 April 2026, providing investors with the latest insights into its performance and prospects.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Solara Active Pharma Sciences Ltd has experienced a nuanced shift in its technical momentum, with recent indicators signalling a transition from bearish to mildly bearish territory. Despite a modest 2.81% gain on 9 Apr 2026, the stock’s broader technical landscape remains complex, reflecting mixed signals from key momentum and trend indicators.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 23 December 2025, reflecting a reassessment of the company’s outlook. However, all fundamentals, returns, and financial metrics discussed here are based on the stock’s current position as of 03 April 2026, providing investors with the latest comprehensive view.

The Sensex advanced 2.49% on 1 Apr 2026, yet Solara Active Pharma Sciences Ltd outpaced the broader market with a 7.83% gain, reaching an intraday high of Rs 459.85. This 6.23-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.07% rise signals a distinctly stock-specific rally rather than a mere market tailwind.

Solara Active Pharma Sciences Ltd’s stock price declined to a fresh 52-week low of Rs.422.85 on 30 March 2026, marking a significant downturn amid broader market weakness and company-specific concerns. The stock has underperformed its sector and benchmark indices, reflecting ongoing challenges in financial performance and investor sentiment.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 March 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 Dec 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Solara Active Pharma Sciences Ltd’s share price declined to a fresh 52-week low of Rs.426.15 today, marking a significant milestone in the stock’s recent downward trajectory amid broader market pressures and company-specific performance concerns.

Solara Active Pharma Sciences Ltd has touched a new 52-week low of Rs.440 today, marking a significant decline in its stock price amid broader market weakness and company-specific concerns. The stock has underperformed its sector and key benchmarks, reflecting ongoing challenges in its financial and market performance.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 11 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Solara Active Pharma Sciences Ltd’s stock declined to a fresh 52-week low of Rs.440.4 on 2 Mar 2026, marking a significant milestone in its ongoing downward trajectory. The stock has underperformed its sector and broader market indices, reflecting persistent pressures on its financial and market performance.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 28 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Solara Active Pharma Sciences Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 February 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Solara Active Pharma Sciences Ltd has reached a new 52-week low, closing at Rs.441 today, marking a significant decline amid a broader market that continues to show resilience. The stock’s recent performance reflects ongoing concerns within the Pharmaceuticals & Biotechnology sector, with the share price underperforming both its peers and the benchmark indices.